A recap of Bio-IT World and DIA 2026

Biopharma organizations are increasingly deploying AI, but they face challenges with "digital debt" due to a vast amount of unstructured, unclassified data accumulated over decades of research and clinical trials. This issue was highlighted at recent industry events where Box demonstrated its solutions for creating an AI-ready content infrastructure. Box Shield Pro, an AI-driven tool, automatically classifies and protects regulated content, reducing classification times and ensuring compliance, which is vital since 90% of biopharma R&D data is unstructured. Without proper metadata, AI tools struggle to operate effectively, risking compliance breaches and data exposure. Box's approach involves using AI to classify and protect data, transforming "dark data" into structured, governed content that AI can safely interact with. At the DIA Global Annual Meeting, experts emphasized that organizations should audit and organize their content infrastructure before pursuing complex AI strategies. Regeneron’s implementation of a secure content management system illustrates the importance of strict governance for fast, error-free collaboration with partners. Overall, the integration of AI in biopharma necessitates a simultaneous focus on content, governance, and execution to turn unclassified data from a liability into an opportunity.

Use this post, company, and trend context to find content marketing opportunities, perform competitive analysis, or address product feature gaps via the Plushcap MCP server or the Plushcap API.